Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human

British Journal of Pharmacology

Volumn 164, Issue 4, 2011, Pages 1322-1334

  Morgan, Michael M ^a   Christie, MacDonald J ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

analgesia; morphine; mu receptor; opioid; opioid efficacy; opioid signalling; withdrawal

Indexed keywords

BUPRENORPHINE; CLONIDINE; CODEINE; DIAMORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ETORPHINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; LEVALLORPHAN; LOFEXIDINE; METENKEPHALIN; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; OPIATE; OXYCODONE; PENTAZOCINE; PETHIDINE; SUFENTANIL;

ANALGESIC ACTIVITY; BEHAVIOR; BRAIN SLICE; CELL CULTURE; CHRONIC PAIN; CONTINUOUS INFUSION; DESENSITIZATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SELF ADMINISTRATION; DRUG TOLERANCE; DRUG WITHDRAWAL; EXPERIMENTAL ANIMAL; HETEROLOGOUS EXPRESSION; HUMAN; HYPERALGESIA; IN VITRO STUDY; INTERNALIZATION; NERVE CELL; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OPIATE ADDICTION; PAIN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ADDICTIVE; BEHAVIOR, ANIMAL; CELL CULTURE TECHNIQUES; DRUG TOLERANCE; HUMANS; OPIOID-RELATED DISORDERS; PAIN; RESEARCH DESIGN;

EID: 80053294982     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01335.x     Document Type: Review

References (120)

1. Adams JU, Paronis CA, Holtzman SG, (1990). Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine. J Pharmacol Exp Ther 255: 1027-1032.
2. Aley KO, Levine JD, (1997). Different mechanisms mediate development and expression of tolerance and dependence for peripheral Âμ-opioid antinociception in the rat. J Neurosci 17: 8018-8023. (Pubitemid 27426237)
3. Alvarez VA, Arttamangkul S, Dang V, Salem A, Whistler JL, Von Zastrow M, et al,. (2002). mu-Opioid receptors: ligand-dependent activation of potassium conductance, desensitization, and internalization. J Neurosci 22: 5769-5776. (Pubitemid 35386500)
4. Arttamangkul S, Quillinan N, Low MJ, von Zastrow M, Pintar J, Williams JT, (2008). Differential activation and trafficking of micro-opioid receptors in brain slices. Mol Pharmacol 74: 972-979.
5. Ballantyne JC, LaForge KS, (2007). Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129: 235-255. (Pubitemid 46754581)
6. Balster RL, (1991). Drug abuse potential evaluation in animals. Br J Addict 86: 1549-1558.
7. Bardo MT, Bevins RA, (2000). Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology (Berl) 153: 31-43. (Pubitemid 32127902)
8. Bardo MT, Neisewander JL, (1986). Single-trial conditioned place preference using intravenous morphine. Pharmacol Biochem Behav 25: 1101-1105. (Pubitemid 17200373)
9. Barrett AC, Cook CD, Terner JM, Craft RM, Picker MJ, (2001). Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids. Psychopharmacology (Berl) 158: 154-164. (Pubitemid 33020834)
10. Berger AC, Whistler JL, (2010). How to design an opioid drug that causes reduced tolerance and dependence. Ann Neurol 67: 559-569.
11. Borgland SL, (2001). Acute opioid receptor desensitization and tolerance: is there a link? Clin Exp Pharmacol Physiol 28: 147-154. (Pubitemid 32193656)
12. Borgland SL, Connor M, Osborne PB, Furness JB, Christie MJ, (2003). Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors. J Biol Chem 278: 18776-18784. (Pubitemid 36799259)
13. Bossert JM, Ghitza UE, Lu L, Epstein DH, Shaham Y, (2005). Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol 526: 36-50. (Pubitemid 41744104)
14. Brady JV, (1991). Animal models for assessing drugs of abuse. Neurosci Biobehav Rev 15: 35-43.
15. Buntin-Mushock C, Phillip L, Moriyama K, Palmer PP, (2005). Age-dependent opioid escalation in chronic pain patients. Anesth Analg 100: 1740-1745. (Pubitemid 40712733)
16. Carter BL, Tiffany ST, (1999). Meta-analysis of cue-reactivity in addiction research. Addiction 94: 327-340. (Pubitemid 29137413)
17. Celver J, Xu M, Jin W, Lowe J, Chavkin C, (2004). Distinct domains of the mu-opioid receptor control uncoupling and internalization. Mol Pharmacol 65: 528-537. (Pubitemid 38264020)
18. Chen Y, Mestek A, Liu J, Hurley JA, Yu L, (1993). Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 44: 8-12. (Pubitemid 23230453)
19. Christie MJ, (2008). Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 154: 384-396. (Pubitemid 351670590)
20. Christie MJ, Williams JT, North RA, (1987). Cellular mechanisms of opioid tolerance: studies in single brain neurons. Mol Pharmacol 32: 633-638. (Pubitemid 18004177)
21. Christie MJ, Connor M, Vaughan CW, Ingram SL, Bagley EE, (2000). Cellular actions of opioids and other analgesics: implications for synergism in pain relief. Clin Exp Pharmacol Physiol 27: 520-523. (Pubitemid 30417998)
22. Clarke WP, Bond RA, (1998). The elusive nature of intrinsic efficacy. Trends Pharmacol Sci 19: 270-276. (Pubitemid 28358086)
23. Cochin J, Kornetsky C, (1964). Development and loss of tolerance to morphine in the rat after single and multiple injections. J Pharmacol Exp Ther 145: 1-10.
24. Collett BJ, (1998). Opioid tolerance: the clinical perspective. Br J Anaesth 81: 58-68.
25. Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, Walsh SL, (2008a). The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 96: 1-15.
26. Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ, (2008b). Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 33: 1179-1191. (Pubitemid 351367537)
27. Cook CD, Barrett AC, Roach EL, Bowman JR, Picker MJ, (2000). Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor. Psychopharmacology (Berl) 150: 430-442. (Pubitemid 30470222)
28. Cowan DT, Allan LG, Libretto SE, Griffiths P, (2001). Opioid drugs: a comparative survey of therapeutic and 'street' use. Pain Med 2: 193-203. (Pubitemid 33138784)
29. Craft RM, (2008). Sex differences in analgesic, reinforcing, discriminative, and motoric effects of opioids. Exp Clin Psychopharmacol 16: 376-385.
30. Craft RM, Tseng AH, McNiel DM, Furness MS, Rice KC, (2001). Receptor-selective antagonism of opioid antinociception in female versus male rats. Behav Pharmacol 12: 591-602. (Pubitemid 34017105)
31. Crombag HS, Bossert JM, Koya E, Shaham Y, (2008). Review. Context-induced relapse to drug seeking: a review. Philos Trans R Soc Lond B Biol Sci 363: 3233-3243.
32. Cushman P, Dole VP, (1973). Detoxification of rehabilitated methadone-maintained patients. JAMA 226: 747-752.
33. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, et al,. (2006). Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 96: 627-632.
34. Dang VC, Williams JT, (2005). Morphine-Induced mu-opioid receptor desensitization. Mol Pharmacol 68: 1127-1132.
35. Dum J, Blasig J, Herz A, (1981). Buprenorphrine: demonstration of physical dependence liability. Eur J Pharmacol 70: 293-300. (Pubitemid 11149322)
36. Duttaroy A, Yoburn BC, (1995). The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 82: 1226-1236.
37. Eisenberg E, McNicol ED, Carr DB, (2005). Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 293: 3043-3052. (Pubitemid 40965075)
38. Farrar JT, Messina J, Xie F, Portenoy RK, (2010). A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain. Pain Med 11: 1313-1327.
39. Fields HL, (2007). Should we be reluctant to prescribe opioids for chronic non-malignant pain? Pain 129: 233-234. (Pubitemid 46754579)
40. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL 3rd, (2009). Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain 10: 447-485.
41. Fishbain DA, Rosomoff HL, Rosomoff RS, (1992). Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain 8: 77-85.
42. Fishbain DA, Cole B, Lewis JE, Gao J, Rosomoff RS, (2009). Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med 10: 829-839.
43. Goode TL, Raffa RB, (1997). An examination of the relationship between mu-opioid antinociceptive efficacy and G-protein coupling using pertussis and cholera toxins. Life Sci 60: PL107-PL113.
44. Gunn A, Bobeck EN, Weber C, Morgan MM, (2010). The influence of non-nociceptive factors on hot-plate latency in rats. J Pain 12: 222-227.
45. Haberstock-Debic H, Kim KA, Yu YJ, von Zastrow M, (2005). Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons. J Neurosci 25: 7847-7857. (Pubitemid 41208657)
46. Haney M, (2009). Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict Biol 14: 9-21.
47. Haney M, Spealman R, (2008). Controversies in translational research: drug self-administration. Psychopharmacology (Berl) 199: 403-419.
48. Hernandez SH, Nelson LS, (2010). Prescription drug abuse: insight into the epidemic. Clin Pharmacol Ther 88: 307-317.
49. Hill HF, Chapman CR, Kornell JA, Sullivan KM, Saeger LC, Benedetti C, (1990). Self-administration of morphine in bone marrow transplant patients reduces drug requirement. Pain 40: 121-129. (Pubitemid 20070780)
50. Hull LC, Llorente J, Gabra BH, Smith FL, Kelly E, Bailey C, et al,. (2010). The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacy. J Pharmacol Exp Ther 332: 1127-1135.
51. Inturrisi CE, (2002). Clinical pharmacology of opioids for pain. Clin J Pain 18: S3-13. (Pubitemid 34815390)
52. Jaffe JH, (1985). Drug addiction and drug abuse. In:, Gilman AG, Goodman LS, Rall TW, Murad F, (eds). The Pharmacological Basis of Therapeutics. Macmillan: New York, pp. 532-581.
53. Jasinski DR, Pevnick JS, Griffith JD, (1978). Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 35: 501-516. (Pubitemid 8337042)
54. Johanson CE, Balster RL, (1978). A summary of the results of a drug self-administration study using substitution procedures in rhesus monkeys. Bull Narc 30: 43-54. (Pubitemid 9164291)
55. Keith DE, Anton B, Murray SR, Zaki PA, Chu PC, Lissin DV, et al,. (1998). mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 53: 377-384. (Pubitemid 28162857)
56. Kieffer BL, Gaveriaux-Ruff C, (2002). Exploring the opioid system by gene knockout. Prog Neurobiol 66: 285-306. (Pubitemid 34518287)
57. Koch T, Widera A, Bartzsch K, Schulz S, Brandenburg LO, Wundrack N, et al,. (2005). Receptor endocytosis counteracts the development of opioid tolerance. Mol Pharmacol 67: 280-287. (Pubitemid 40069989)
58. Koob GF, Le Moal M, (1997). Drug abuse: hedonic homeostatic dysregulation. Science 278: 52-58. (Pubitemid 27446270)
59. Koob GF, Maldonado R, Stinus L, (1992). Neural substrates of opiate withdrawal. Trends Neurosci 15: 186-191.
60. Kovoor A, Celver JP, Wu A, Chavkin C, (1998). Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. Mol Pharmacol 54: 704-711. (Pubitemid 28480974)
61. Kumar P, Sunkaraneni S, Sirohi S, Dighe SV, Walker EA, Yoburn BC, (2008). Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation. Eur J Pharmacol 597: 39-45.
62. Laschka E, Teschemacher H, Mehraein P, Herz A, (1976). Sites of action of morphine involved in the development of physical dependence in rats. II. Morphine withdrawal precipitated by application of morphine antagonists into restricted parts of the ventricular system and by microinjection into various brain areas. Psychopharmacologia 46: 141-147.
63. Law PY, Erickson LJ, El-Kouhen R, Dicker L, Solberg J, Wang W, et al,. (2000). Receptor density and recycling affect the rate of agonist-induced desensitization of mu-opioid receptor. Mol Pharmacol 58: 388-398. (Pubitemid 30497483)
64. Le Bars D, Gozariu M, Cadden SW, (2001). Animal models of nociception. Pharmacol Rev 53: 597-652. (Pubitemid 33136239)
65. Lett BT, (1989). Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine, and cocaine. Psychopharmacology (Berl) 98: 357-362. (Pubitemid 19162424)
66. Lobmaier P, Gossop M, Waal H, Bramness J, (2010). The pharmacological treatment of opioid addiction-a clinical perspective. Eur J Clin Pharmacol 66: 537-545.
67. Lu L, Shepard JD, Hall FS, Shaham Y, (2003). Effect of environmental stressors on opiate and psychostimulant reinforcement, reinstatement and discrimination in rats: a review. Neurosci Biobehav Rev 27: 457-491. (Pubitemid 37162553)
68. McBride WJ, Murphy JM, Ikemoto S, (1999). Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. Behav Brain Res 101: 129-152. (Pubitemid 29236359)
69. McCormack K, Prather P, Chapleo C, (1998). Some new insights into the effects of opioids in phasic and tonic nociceptive tests. Pain 78: 79-98. (Pubitemid 28517946)
70. Macey TA, Lowe JD, Chavkin C, (2006). Mu opioid receptor activation of ERK1/2 is GRK3 and arrestin dependent in striatal neurons. J Biol Chem 281: 34515-34524. (Pubitemid 46036659)
71. Macey TA, Bobeck EN, Hegarty DM, Aicher SA, Ingram SL, Morgan MM, (2009). Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat. J Pharmacol Exp Ther 331: 412-418.
72. McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, et al,. (2010). mu-Opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 78: 756-766.
73. Madia PA, Dighe SV, Sirohi S, Walker EA, Yoburn BC, (2009). Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse. Psychopharmacology (Berl) 207: 413-422.
74. Mathews JL, Smrcka AV, Bidlack JM, (2008). A novel Gbetagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence. J Neurosci 28: 12183-12189.
75. Melief EJ, Miyatake M, Bruchas MR, Chavkin C, (2010). Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A 107: 11608-11613.
76. Mitrovic I, Margeta-Mitrovic M, Bader S, Stoffel M, Jan LY, Basbaum AI, (2003). Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha 2-adrenergic analgesia and analgesic sex differences. Proc Natl Acad Sci U S A 100: 271-276. (Pubitemid 36078064)
77. Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P, et al,. (1999). Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain 80: 67-82. (Pubitemid 29151691)
78. Morgan MM, Fossum EN, Levine CS, Ingram SL, (2006a). Antinociceptive tolerance revealed by cumulative intracranial microinjections of morphine into the periaqueductal gray in the rat. Pharmacol Biochem Behav 85: 214-219. (Pubitemid 44772923)
79. Morgan MM, Fossum EN, Stalding BM, King MM, (2006b). Morphine antinociceptive potency on chemical, mechanical, and thermal nociceptive tests in the rat. J Pain 7: 358-366.
80. Narita M, Ioka M, Suzuki M, Suzuki T, (2002). Effect of repeated administration of morphine on the activity of extracellular signal regulated kinase in the mouse brain. Neurosci Lett 324: 97-100. (Pubitemid 34457814)
81. Nestler EJ, (2004). Molecular mechanisms of drug addiction. Neuropharmacology 47 (Suppl. 1): 24-32. (Pubitemid 39298250)
82. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al,. (2010). Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 20: CD006605.
83. Patel MB, Patel CN, Rajashekara V, Yoburn BC, (2002). Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo. Mol Pharmacol 62: 1464-1470. (Pubitemid 35403842)
84. Pawar M, Kumar P, Sunkaraneni S, Sirohi S, Walker EA, Yoburn BC, (2007). Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2. Eur J Pharmacol 563: 92-101. (Pubitemid 46602222)
85. Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al,. (2008). Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8: 287-313.
86. Portenoy RK, (1994). Tolerance to opioid analgesics: clinical aspects. Cancer Surv 21: 49-65. (Pubitemid 24355813)
87. Portenoy RK, Farrar JT, Backonja MM, Cleeland CS, Yang K, Friedman M, et al,. (2007). Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain 23: 287-299. (Pubitemid 46650020)
88. Przewlocki R, Przewlocka B, (2001). Opioids in chronic pain. Eur J Pharmacol 429: 79-91. (Pubitemid 33043984)
89. Richardson NR, Roberts DC, (1996). Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66: 1-11. (Pubitemid 26180064)
90. Rosenberg H, (2009). Clinical and laboratory assessment of the subjective experience of drug craving. Clin Psychol Rev 29: 519-534.
91. Saidak Z, Blake-Palmer K, Hay DL, Northup JK, Glass M, (2006). Differential activation of G-proteins by mu-opioid receptor agonists. Br J Pharmacol 147: 671-680.
92. Schindler CW, Panlilio LV, Goldberg SR, (2002). Second-order schedules of drug self-administration in animals. Psychopharmacology (Berl) 163: 327-344.
93. Selley DE, Liu Q, Childers SR, (1998). Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther 285: 496-505. (Pubitemid 28237424)
94. Shalev U, Grimm JW, Shaham Y, (2002). Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 54: 1-42. (Pubitemid 34208828)
95. Sinha R, (2001). How does stress increase risk of drug abuse and relapse? Psychopharmacology (Berl) 158: 343-359. (Pubitemid 33141310)
96. Sirohi S, Dighe SV, Walker EA, Yoburn BC, (2008). The analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulation. Pharmacol Biochem Behav 91: 115-120.
97. Sittl R, Nuijten M, Nautrup BP, (2006). Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. Clin Ther 28: 1144-1154. (Pubitemid 44374747)
98. Sosnowski M, Yaksh TL, (1990). Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anesthesiology 73: 1141-1147.
99. Stevens CW, Yaksh TL, (1989). Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion. J Pharmacol Exp Ther 250: 1-8. (Pubitemid 19194967)
100. Stevens CW, Monasky MS, Yaksh TL, (1988). Spinal infusion of opiate and alpha-2 agonists in rats: tolerance and cross-tolerance studies. J Pharmacol Exp Ther 244: 63-70. (Pubitemid 18042363)
101. Strange PG, (2008). Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br J Pharmacol 153: 1353-1363. (Pubitemid 351492449)
102. Tate CG, Grisshammer R, (1996). Heterologous expression of G-protein-coupled receptors. Trends Biotechnol 14: 426-430. (Pubitemid 26365981)
103. Terner JM, Lomas LM, Smith ES, Barrett AC, Picker MJ, (2003). Pharmacogenetic analysis of sex differences in opioid antinociception in rats. Pain 106: 381-391. (Pubitemid 37505886)
104. Tobias JD, (2000). Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit. Crit Care Med 28: 2122-2132. (Pubitemid 30428787)
105. Trafton JA, Abbadie C, Marek K, Basbaum AI, (2000). Postsynaptic signaling via the [mu]-opioid receptor: responses of dorsal horn neurons to exogenous opioids and noxious stimulation. J Neurosci 20: 8578-8584.
106. Traynor JR, Nahorski SR, (1995). Modulation by mu-opioid agonists of guanosine-5â-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 47: 848-854.
107. Vaughan CW, Ingram SL, Connor MA, Christie MJ, (1997). How opioids inhibit GABA-mediated neurotransmission. Nature 390: 611-614. (Pubitemid 28016195)
108. Vera-Portocarrero LP, Zhang ET, King T, Ossipov MH, Vanderah TW, Lai J, et al,. (2007). Spinal NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways. Pain 129: 35-45. (Pubitemid 46551368)
109. Walker EA, Young AM, (2001). Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats. Psychopharmacology (Berl) 154: 131-142. (Pubitemid 32186498)
110. Walker EA, Zernig G, Young AM, (1998). In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail-withdrawal assay. Psychopharmacology (Berl) 136: 15-23. (Pubitemid 28097516)
111. Werz MA, Macdonald RL, (1982). Opioid peptides decrease calcium-dependent action potential duration of mouse dorsal root ganglion neurons in cell culture. Brain Res 239: 315-321. (Pubitemid 12101794)
112. Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M, (1999). Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23: 737-746. (Pubitemid 29411563)
113. Williams JT, Christie MJ, Manzoni O, (2001). Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 81: 299-343. (Pubitemid 32096178)
114. Wilson SG, Smith SB, Chesler EJ, Melton KA, Haas JJ, Mitton B, et al,. (2003). The heritability of antinociception: common pharmacogenetic mediation of five neurochemically distinct analgesics. J Pharmacol Exp Ther 304: 547-559. (Pubitemid 36152329)
115. Winger G, Woods JH, (2001). The effects of chronic morphine on behavior reinforced by several opioids or by cocaine in rhesus monkeys. Drug Alcohol Depend 62: 181-189. (Pubitemid 32276065)
116. Yu Y, Zhang L, Yin X, Sun H, Uhl GR, Wang JB, (1997). Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem 272: 28869-28874. (Pubitemid 27498167)
117. Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ, (2010). Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci 1187: 184-207.
118. Zaki PA, Keith DE, Jr, Brine GA, Carroll FI, Evans CJ, (2000). Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther 292: 1127-1134. (Pubitemid 30136610)
119. Zeng J, Thomson LM, Aicher SA, Terman GW, (2006). Primary afferent NMDA receptors increase dorsal horn excitation and mediate opiate tolerance in neonatal rats. J Neurosci 26: 12033-12042. (Pubitemid 44772114)
120. Zhou D, Chen ML, Zhang YQ, Zhao ZQ, (2010). Involvement of spinal microglial P2X7 receptor in generation of tolerance to morphine analgesia in rats. J Neurosci 30: 8042-8047.